Clinical Trials Browser

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

NCT03961971 2025-09-10

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Phase 1 Active not recruiting

16 enrolled

CNS

Glioblastoma

NCT06512207 2025-09-09

A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

Phase NA Recruiting

80 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07007182 2025-09-05

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

Phase 2 Not yet recruiting

54 enrolled

Gastrointestinal

Stomach Neoplasms

NCT06255223 2025-09-03

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

Phase 2 Recruiting

35 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05576480 2025-08-28

SPARC

Phase 2 Recruiting

55 enrolled

Gastrointestinal

Rectal Neoplasms

NCT04191421 2025-08-22

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

Phase 1/2 Completed

35 enrolled 10 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04028245 2025-08-07

SPARC-1

Phase EARLY_PHASE1 Active not recruiting

17 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04572451 2025-08-01

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Phase 1 Recruiting

50 enrolled

Dermatologic

Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site

NCT05978102 2025-07-23

A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

Phase 1/2 Recruiting

183 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06377111 2025-07-14

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

Phase 1 Recruiting

12 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT07053150 2025-07-08

CCGLC-018

Phase 2 Not yet recruiting

80 enrolled

Advanced Digestive System Tumor

NCT06507371 2025-06-26

mRCAT-III

Phase 3 Recruiting

170 enrolled

Gastrointestinal

Rectal Neoplasms

NCT03815942 2025-06-25

ADVANCE

Phase 1/2 Terminated

23 enrolled 11 charts

Genitourinary

Intermediate Risk Prostate Cancer

NCT06728657 2025-06-18

TORCH-G

Phase 2 Suspended

68 enrolled

Gastrointestinal

Stomach Adenocarcinoma

NCT06013618 2025-06-17

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Phase 2 Recruiting

120 enrolled

CNS

Neuroblastoma

NCT03294694 2025-05-31

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Phase 1 Terminated

33 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

NCT04821765 2025-05-30

Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer

Phase 2 Completed

35 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT06280495 2025-05-30

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Phase 2/3 Recruiting

156 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06802835 2025-05-16

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Phase 1/2 Recruiting

148 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT06908031 2025-05-14

CRIT

Phase 2 Recruiting

49 enrolled

Gastrointestinal

Rectal Neoplasms

NCT06794086 2025-05-13

SPARKLE-L

Phase 3 Recruiting

24 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04581343 2025-05-04

PanCAN-SR1

Phase 1 Completed

10 enrolled 26 charts

Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

NCT03958383 2025-04-18

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

Phase 1/2 Active not recruiting

8 enrolled

Dermatologic

Melanoma

NCT06928584 2025-04-15

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

Phase 2 Recruiting

221 enrolled

Gastrointestinal

Locally Recurrent Rectal Cancer

NCT06900218 2025-04-02

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

Phase 3 Not yet recruiting

664 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05713994 2025-03-25

CCGLC-001

Recruiting

300 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04866836 2025-03-21

A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

Phase 2 Terminated

20 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT06840665 2025-02-21

MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

Phase 2 Recruiting

46 enrolled

Gastrointestinal

Locally Advanced Rectal Cancer

NCT03991130 2025-02-06

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

Phase 2 Terminated

6 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis

NCT06792162 2025-01-24

PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

Phase 2 Recruiting

20 enrolled

Gastrointestinal

Stomach Neoplasms

Clinical Trials

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

FEMUS

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

PLUTO

Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma

TORCH-iTNT

Neo-CD

ROSETTE

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

NLCCRIT-LARC

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

SPARC

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

SPARC-1

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

CCGLC-018

mRCAT-III

ADVANCE

TORCH-G

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

CRIT

SPARKLE-L

PanCAN-SR1

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

CCGLC-001

A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer